Abstract: A laser source (101) comprises: (i) a first beam generating configuration (111, 112, 113) adapted to generate a pulsed primary ablating laser beam (162) with pulses having a first emission spectrum and a first temporal pulse width to ablate one type of tissue, (ii) a second beam generating configuration (121, 122, 123) adapted to generate a pulsed secondary ablating laser beam (163) with pulses having a second emission spectrum different from the first emission spectrum and a second temporal pulse width to ablate another type of tissue different than the one type of tissue ablated by the primary laser beam (162), (iii) a third beam generating configuration (121, 122, 123, 126) adapted to generate a pulsed analysis laser beam (161) with at least one pulse having a third emission spectrum and a third temporal pulse width shorter than the first temporal pulse width and shorter than the second temporal pulse width, and (iv) a beam directing optics (125) with beam aligning elements adapted to align the primary abl

Abstract: A laser device (100) has an ablation laser source (401) adapted to provide an ablating laser beam (402; 402i) for ablating a target tissue (120). It further comprises a plume analyzing arrangement (250) adapted to identify and/or quantify substances in the debris of the plume (110) generated by the ablating laser beam (402) ablating the target tissue (120) particularly substances being biomarkers of the ablated target tissue (120).

Abstract: The invention relates to N-phenyl-2-pyrimidine-amine derivatives derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.

Abstract: The invention relates to N-phenyl-2-pyrimidine-amine derivatives derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.

Abstract: The invention relates to N-phenyl-2-pyrimidine-amine derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans.